Kim D Bullock, MD
Psychiatry · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Research they published
43 papers · cited 1,662 times
Published as Kim D. Bullock at Stanford Medicine, Stanford University.
Research identity is not a guarantee of current clinical practice. Same name is not the same person — if this looks like someone else, tell us.
| 2025 | Treatments for Functional Neurological Disorder: A Practical Guide for Program Development | Journal of Neuropsychiatry |
| 2024 | Feasibility and Acceptability of a Mobile App–Based TEAM-CBT (Testing Empathy Assessment Methods–Cognitive Behavioral Therapy) Intervention (Feeling Good) for Depression: Secondary Data AnalysisLast author | JMIR Mental Health |
| 2024 | Examining the Efficacy of Extended Reality–Enhanced Behavioral Activation for Adults With Major Depressive Disorder: Randomized Controlled Trial | JMIR Mental Health |
| 2023 | Augmenting group hoarding disorder treatment with virtual reality discarding: A pilot study in older adults | Journal of Psychiatric Research |
| 2023 | A Systematic Review of using Virtual and Augmented Reality for the Diagnosis and Treatment of Psychotic Disorders | Current Treatment Options in Psychiatry |
| 2023 | Functional neurological disorder is a feminist issue | Journal of Neurology Neurosurgery & Psychiatry |
See the 22 most recent papers
| 2022 | Virtual Reality Behavioral Activation for Adults With Major Depressive Disorder: Feasibility Randomized Controlled Trial | JMIR Mental Health |
| 2021 | Translating Virtual Reality Cue Exposure Therapy for Binge Eating into a Real-World Setting: An Uncontrolled Pilot Study | Journal of Clinical Medicine |
| 2020 | Virtual Reality Behavioral Activation as an Intervention for Major Depressive Disorder: Case Report | JMIR Mental Health |
| 2020 | COVID-19 and mental health: A review and the role of telehealth and virtual reality | Digital Medicine |
| 2020 | Bringing Virtual Reality From Clinical Trials to Clinical Practice for the Treatment of Eating Disorders: An Example Using Virtual Reality Cue Exposure Therapy | Journal of Medical Internet Research |
| 2019 | Virtual Reality-Delivered Mirror Visual Feedback and Exposure Therapy for FND: A Midpoint Report of a Randomized Controlled Feasibility StudyFirst author | Journal of Neuropsychiatry |
| 2019 | Key Considerations for Incorporating Conversational AI in Psychotherapy | Frontiers in Psychiatry |
| 2018 | Recommendations for Methodology of Virtual Reality Clinical Trials in Health Care by an International Working Group: Iterative Study | JMIR Mental Health |
| 2015 | Group Dialectical-Behavior Therapy Skills Training for Conversion Disorder With SeizuresFirst author | Journal of Neuropsychiatry |
| 2008 | Group therapy for patients with psychogenic nonepileptic seizures: A pilot study | Epilepsy & Behavior |
| 2005 | Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder | The Journal of Clinical Psychiatry |
| 2004 | Current Status of the Utilization of Antiepileptic Treatments in Mood, Anxiety and Aggression: Drugs and DevicesLast author | Clinical EEG and Neuroscience |
| 2003 | Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. | PubMed |
| 2003 | Psychopharmacology of compulsive buyingFirst author | Drugs of today |
| 2002 | Citalopram Treatment of Compulsive Shopping | The Journal of Clinical Psychiatry |
| 1992 | Reduced Mortality Risk in Alcoholics Who Achieve Long-term AbstinenceFirst author | JAMA |
Topics: Virtual Reality Applications and Impacts · Obsessive-Compulsive Spectrum Disorders · Psychosomatic Disorders and Their Treatments · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Digital Mental Health Interventions
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bullock’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A56037 · Current
Licensed to practise in California · since 1996 · expires 2028-05-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$63,631
Medicare paid this office $63,631 for 26 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 17 | $33,010 | $170 |
| Psychotherapy with evaluation and management visit, 1 hour | 19 | $21,266 | $110 |
| Group psychotherapy | 13 | $5,307 | $25 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $989 | $15 |
Who their Medicare patients are
26 Original Medicare patients in 2024. Average age 65 · 85 and older 0% · Health risk score 1.09. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 73% · High blood pressure 50%.
The office billed $265,010, Medicare allowed $80,680 and paid $63,631; for 696 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 26 | 696 | 65 | 1.09 | $265,010 | $63,631 |
| 2023 | 25 | 733 | 62 | 1.12 | $199,388 | $32,503 |
| 2022 | 24 | 518 | 63 | 1.21 | $161,705 | $26,381 |
| 2021 | 13 | 305 | 66 | 1.29 | $89,758 | $16,145 |
| 2020 | 12 | 323 | 56 | 1.43 | $93,537 | $18,486 |
| 2019 | 11 | 78 | 69 | 1.12 | $29,031 | $6,443 |
| 2018 | 18 | 120 | 57 | 1.12 | $15,195 | $8,341 |
| 2017 | 22 | 51 | 60 | 1.09 | $6,745 | $2,695 |
| 2016 | 20 | 94 | 59 | 0.91 | $16,336 | $6,293 |
| 2015 | 18 | 261 | 55 | 1.31 | $39,510 | $17,264 |
| 2014 | 16 | 327 | 52 | 1.07 | $47,034 | $20,871 |
| 2013 | 21 | 263 | 58 | 1.15 | $41,790 | $13,856 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Psychotherapy with evaluation and management visit, 1 hour | 15 | $8,234 | $107 |
| Return visit (30+ min) | 11 | $7,080 | $118 |
| Telehealth originating site facility fee | 24 | $6,696 | $21 |
| Group psychotherapy | 16 | $5,461 | $23 |
| Long return visit (40+ min) | 11 | $3,603 | $172 |
2022: 2 services
| Telehealth originating site facility fee | 23 | $4,642 | $21 |
| Group psychotherapy | 15 | $3,420 | $24 |
2021: 1 service
| Telehealth originating site facility fee | 12 | $2,746 | $21 |
2013: 1 service
| Return visit (30+ min) | 12 | $5,275 | $54 |
Drugs they prescribed that Part D paid
$594
Pharmacies billed $594 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 41) in 2024. Too few prescriptions to compare fairly with other clinicians.
41 generic and 0 brand-name prescriptions · $594 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Quetiapine | 12 | $97 | $8 |
Year by year
| 2024 | 41 | None | 0% (0) | 0% | $594 |
| 2023 | 24 | None | 0% (0) | 0% | $649 |
| 2022 | 24 | None | 0% (0) | 0% | $2,635 |
| 2021 | 19 | None | 0% (0) | 0% | $683 |
| 2020 | 30 | None | 0% (0) | 0% | $567 |
| 2019 | 26 | None | 0% (0) | 0% | $1,213 |
| 2018 | 24 | None | 0% (0) | 0% | $1,558 |
| 2017 | 23 | None | 0% (0) | 0% | $928 |
| 2016 | 41 | None | 0% (0) | 0% | $1,321 |
| 2015 | 58 | None | 0% (0) | 0% | $1,350 |
| 2014 | 50 | None | 0% (0) | 0% | $7,221 |
| 2013 | 71 | None | None | None | $15,075 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2016: 1 drug
| Quetiapine | 12 | $518 | $43 |
2015: 2 drugs
| Quetiapine | 11 | $449 | $41 |
| Lamotrigine | 16 | $218 | $14 |
2014: 1 drug
| Quetiapine | 17 | $6,189 | $364 |
2013: 2 drugs
| Quetiapine | 19 | $9,877 | $520 |
| Clonazepam | 22 | $99 | $5 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790842763
- Licence
- CA A56037California A56037: Current · expires 2028-05-31
- Trained
- George Washington University School of Medicine, 1994
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-02
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 401 Quarry Rd, Palo Alto, CA, 94304